Forsteo ® (teriparatid)

För fullständig produktresumé för Forsteo® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Forsteo® (teriparatide): Användning efter strålbehandling

Forsteo är kontraindicerat hos patienter med tidigare strålbehandling av skelettet (utvärtes eller genom implantat). Forsteo ska inte förskrivas till patienter som tidigare fått strålbehandling.

Further information

Radiation-induced osteosarcoma is a rare, but well-recognized, complication in human radiotherapy patients. Patients who have had prior radiation therapy have an increased risk of developing a radiogenic second malignant neoplasm, including osteosarcoma, some years or decades after initial treatment.1,2

Forsteo is contraindicated in patients with prior external beam or implant radiation therapy to the skeleton.3

Examples of prior radiation therapy where teriparatide should not be used

Use of teriparatide should be avoided in patients who previously received

  • external beam radiation (stereotactic radiation), and

  • internal radiation (brachytherapy, interstitial radiation, intracavitary radiation).4,5

Radiation affecting any area of the skeleton should be avoided.5

Examples of prior radiation therapy where teriparatide may be considered

  • Radioactive iodine therapy5

  • Low doses of non-penetrative radiation, such as Grenz radiation, for treatment of skin conditions5

  • Diagnostic radiation such as computed tomography scans, radiographs, and radionuclide scans5

  • Non-radioactive forms of radiation such as ultraviolet radiation and phototherapy5

References

1. Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br. 2007;89-B(6):808-813. http://dx.doi.org/10.1302/0301-620X.89B6.18729

2. Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer. 2011;11(6):438-448. http://dx.doi.org/10.1038/nrc3069

3. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

4. American Cancer Society. Radiation therapy. Accessed February 4, 2020. http://www.cancer.org/acs/groups/cid/documents/webcontent/003019-pdf.pdf

5. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Datum fӧr senaste ӧversyn 2020 M02 05


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss